Molecular pathogenesis and systemic therapies for hepatocellular carcinoma
Open accessAbstract
Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers. The poor outcome associated with HCC is dramatically changing due to the advent of effective systemic therapies. Here we discuss the molecular pathogenesis of HCC, molecular classes and determinants of heterogeneity. In addition, effective single-agent and combination systemic therapies involving immunotherapies as standard of care are analyzed. Finally, we propose a flowchart of sequential therapies, explore mechanisms of resistance and address the need for predictive biomarkers.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Improvements in systemic therapy for advanced hepatocellular carcinoma have not been matched by improved treatment of early-stage disease.
“However, this remarkable progress in systemic therapy has not been paralleled by improvements in the treatment of early stage HCC, which typically involves administration of therapies with curative intent, such as resection, liver transplantation or local ablation1,2.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [2]
The Introduction describes major advances in systemic therapy, and 'Placing systemic therapies in the context of HCC management' identifies resection, transplantation and ablation as curative options for early-stage HCC. 'Future directions' calls neoadjuvant and adjuvant therapies an unmet need, but the paper does not establish the broader claim that early-stage treatment has not improved. (LLM, conf=0.84)
Experimental — accuracy not yet measuredFor advanced HCC, about 10 systemic regimens have shifted median overall survival from 6-8 months to 19-20 months after first-line treatment and 10-14 months after second-line treatment.
“For patients with advanced-stage HCC, the current availability of ~10 systemic regimens1,2,5,35,40 has resulted in a shift from median OS durations of 6–8 months to 19–20 months after first-line treatment and 10–14 months after second-line treatment (Fig. 4a).”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [2]
The paper’s “Current systemic therapies in HCC” section lists eight approved regimens, plus two combinations with recently reported trial results; it does not establish that about ten regimens were available. “Selection of patients and expected outcomes” reports about 19 months’ survival with one first-line combination, but 13–14 months with other first-line treatments and 8–11 months with the second-line treatments it discusses. The first-line trials section reports 7.9 months for placebo, broadly consistent with the claimed earlier baseline, but the paper does not support the stated 10–14-month second-line range or attribute the entire survival shift to the availability of regimens alone. Page numbers were not provided in our copy. (LLM, conf=0.88)
Experimental — accuracy not yet measuredEffective systemic therapies, especially immune-checkpoint inhibitors, have substantially improved outcomes for patients with advanced-stage hepatocellular carcinoma.
“Over the past two decades, the development of effective systemic therapies has substantially improved the outcomes of patients with advanced-stage HCC2–6.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [2]
After resection or local ablation, median overall survival exceeds 60 months, but 30-50% of patients have recurrence by 3 years.
“Despite an impressive median overall survival (OS) beyond 60 months after resection or local ablation, up to 30–50% of patients have disease recurrence at 3 years, often resulting from intrahepatic metastases or de novo tumours arising in the underlying liver pathology1,2.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [2]
The ‘Placing systemic therapies in the context of HCC management’ section (page unavailable) identifies resection and ablation as curative options for early-stage HCC, but gives neither median survival after those treatments nor a three-year recurrence rate. Searches for 60-month survival, three-year recurrence, and recurrence after resection or ablation found no passage supporting those figures; the paper’s 30–50% figures refer to other populations or treatments. (LLM, conf=0.75)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097 · see citing works
Self-citationEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406 · see citing works
Self-citationAtezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470 · see citing works
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S. A., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,173 · see citing works
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055 · see citing works
Self-citationCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · see citing works
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974 · see citing works
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832 · see citing works
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497 · see citing works
Acute Abdomen: A Rare Case of Ruptured Hepatocellular Carcinoma
Gloor, S., Jensen, K. O., Breitenstein, S., Binkert, C. A., Angst, E., & Hetzer, F. H. (2017) · Case Reports in Gastroenterology · doi:10.1159/000463378 · Cited by 5,370 · see citing works
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218 · see citing works
Marrero, J. A., Kulik, L., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018) · Hepatology · doi:10.1002/hep.29913 · Cited by 4,549 · see citing works
Villanueva, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1713263 · Cited by 4,508 · see citing works
Self-citationEl-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280 · see citing works
Self-citationA global view of hepatocellular carcinoma: trends, risk, prevention and management
Yang, J. D., Hainaut, P. L., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0186-y · Cited by 4,233 · see citing works
Self-citationThe landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017 · see citing works
Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
Llovet, J., Brú, C., & Bruix, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007122 · Cited by 3,805 · see citing works
Self-citationBruix, J., Qin, S., Merle, P., Granito, A., Huang, Y., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,657 · see citing works
Self-citationLlovet, J. M., Burroughs, A. K., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,613 · see citing works
Self-citationZehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · see citing works
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162 · see citing works
Expanding consensus in portal hypertension
de Franchis, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.022 · Cited by 3,078 · see citing works
Clonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840 · see citing works
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490 · see citing works
Self-citationZhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479 · see citing works
Self-citationCabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Abou‐Alfa, G. K., Meyer, T., Cheng, A., El-Khoueiry, A. B., Rimassa, L., Ryoo, B., Çiçin, İ., Merle, P., Chen, Y.-H., Park, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1717002 · Cited by 2,347 · see citing works
Self-citationRenal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Escudier, B. J., Porta, C., Schmidinger, M., Ferran Algaba, B., Patard, J., Khoo, V. S., Eisen, T. G., & Horwich, A. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu259 · Cited by 2,253 · see citing works
Omata, M., Cheng, A., Kokudo, N., Kudo, M., Lee, J. M., Jia, J., Tateishi, R., Han, K., Chawla, Y. K., Shiina, S., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9799-9 · Cited by 2,187 · see citing works
Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing
Zheng, C., Zheng, L., Yoo, J.-K., Guo, H., Zhang, Y., Guo, X., Kang, B., Hu, R., Huang, J. Y., Zhang, Q., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.035 · Cited by 2,152 · see citing works
Molecular therapies and precision medicine for hepatocellular carcinoma
Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0073-4 · Cited by 1,948 · see citing works
Self-citationImmunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843 · see citing works
Self-citationSchulze, K., Imbeaud, S., Letouzé, E., Alexandrov, L. B., Calderaro, J., Rebouissou, S., Couchy, G., Meiller, C., Shinde, J., Soysouvanh, F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3252 · Cited by 1,803 · see citing works
Self-citationFinn, R. S., Ryoo, B.-Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., Breder, V., Edeline, J., Chao, Y., Ogasawara, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01307 · Cited by 1,789 · see citing works
Cheng, A.-L., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Lim, H. Y., Kudo, M., Breder, V., Merle, P., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.030 · Cited by 1,743 · see citing works
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
Costa, A., Kieffer, Y., Scholer-Dahirel, A., Pelon, F., Bourachot, B., Cardon, M., Sirven, P., Magagna, I., Fuhrmann, L., Bernard, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.011 · Cited by 1,705 · see citing works
Zhu, A. X., Kang, Y., Yen, C., Finn, R. S., Galle, P. R., Llovet, J. M., Assénat, E., Brandi, G., Pracht, M., Lim, H. Y., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30937-9 · Cited by 1,666 · see citing works
Self-citationLandscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma
Zhang, Q., He, Y., Luo, N., Patel, S. J., Han, Y., Gao, R., Modak, M., Carotta, S., Haslinger, C., Kind, D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.003 · Cited by 1,624 · see citing works
Integrative single-cell analysis
Stuart, T., & Satija, R. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0093-7 · Cited by 1,460 · see citing works
Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.25864 · Cited by 1,355 · see citing works
Yakes, F. M., Chen, J., Tan, J., Yamaguchi, T., Shi, Y., Yu, P., Qian, F., Chu, F., Bentzien, F., Cancilla, B., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0264 · Cited by 1,350 · see citing works
Genetic landscape and biomarkers of hepatocellular carcinoma
Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325 · see citing works
Self-citationAdvances in immunotherapy for hepatocellular carcinoma
Sangro, B., Sarobe, P., Hervás-Stubbs, S., & Melero, I. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00438-0 · Cited by 1,306 · see citing works
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302 · see citing works
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Pfister, D., Núñez, N. G., Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., Gupta, R., Qiu, M., Deczkowska, A., Weiner, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03362-0 · Cited by 1,294 · see citing works
Self-citationYau, T., Kang, Y.-K., Kim, T.-Y., El-Khoueiry, A. B., Santoro, A., Sangro, B., Melero, I., Kudo, M., Hou, M.-M., Matilla, A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4564 · Cited by 1,273 · see citing works
Self-citationDeciphering cell–cell interactions and communication from gene expression
Armingol, E., Officer, A., Harismendy, O., & Lewis, N. E. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-020-00292-x · Cited by 1,267 · see citing works
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets
Boyault, S., Rickman, D. S., de Reyniès, A., Balabaud, C., Rebouissou, S., Jeannot, E., Hérault, A., Saric, J., Belghiti, J., Franco, D., et al. (2007) · Hepatology · doi:10.1002/hep.21467 · Cited by 1,258 · see citing works
Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238 · see citing works
Self-citationSu, S., Chen, J., Yao, H., Liu, J., Yu, S., Lao, L., Wang, M., Luo, M., Xing, Y., Chen, F., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.009 · Cited by 1,230 · see citing works
Finn, R. S., Ikeda, M., Zhu, A. X., Sung, M. W., Baron, A. D., Kudo, M., Okusaka, T., Kobayashi, M., Kumada, H., Kaneko, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00808 · Cited by 1,167 · see citing works
Self-citationLiver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
Sia, D., Villanueva, A., Friedman, S., & Llovet, J. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.11.048 · Cited by 1,051 · see citing works
Self-citationHepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Vogel, A., Cervantes, A. M. R., Chau, I., Daniele, B., Llovet, J. M., Meyer, T., Nault, J., Neumann, U. P., Ricke, J., Sangro, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy308 · Cited by 1,047 · see citing works
Self-citationLocoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Llovet, J. M., De Baere, T., Kulik, L., Haber, P. K., Greten, T. F., Meyer, T., & Lencioni, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00395-0 · Cited by 1,044 · see citing works
Self-citationHepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., D'Angelica, M. I., Abbott, D. E., Anaya, D. A., Anders, R. A., Are, C., Bachini, M., Borad, M. J., Brown, D. B., Burgoyne, A. M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0022 · Cited by 1,010 · see citing works
Self-citationLiver regeneration: biological and pathological mechanisms and implications
Michalopoulos, G. K., & Bhushan, B. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0342-4 · Cited by 998 · see citing works
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Sia, D., Jiao, Y., Martinez-Quetglas, I., Kuchuk, O., Villacorta-Martin, C., Castro de Moura, M., Putra, J., Camprecios, G., Bassaganyas, L., Akers, N., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.007 · Cited by 976 · see citing works
Self-citationCombination of CTLA-4 and PD-1 blockers for treatment of cancer
Rotte, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1259-z · Cited by 968 · see citing works
Targeted protein degradation: expanding the toolbox
Schapira, M., Calabrese, M. F., Bullock, A. N., & Crews, C. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0047-y · Cited by 960 · see citing works
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells
Lee, J., Heo, J., Libbrecht, L. J., Chu, I., Kaposi-Novák, P., Calvisi, D. F., Mikaelyan, A. S., Roberts, L. R., Demetris, A. J., Sun, Z., et al. (2006) · Nature Medicine · doi:10.1038/nm1377 · Cited by 953 · see citing works
Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma
Sun, Y., Wu, L. L., Zhong, Y., Zhou, K., Hou, Y., Wang, Z., Zhang, Z., Xie, J., Wang, C., Chen, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.11.041 · Cited by 893 · see citing works
Self-citationZhu, A. X., Park, J. O., Ryoo, B., Yen, C.-J., Poon, R. T. P., Pastorelli, D., Blanc, J., Chung, H. C., Baron, A. D., Pfiffer, T., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00050-9 · Cited by 845 · see citing works
Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer
Ma, L., Hernandez, M. O., Zhao, Y., Mehta, M., Tran, B. Q., Kelly, M. C., Rae, Z., Hernandez, J. M., Davis, J. L., Martin, S. P., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.007 · Cited by 844 · see citing works
Self-citationVilgrain, V., Pereira, H., Assénat, E., Guiu, B., Ilonca, A. D., Pageaux, G., Sibert, A., Bouattour, M., Lebtahi, R., Allaham, W., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30683-6 · Cited by 833 · see citing works
Bruix, J., Raoul, J., Sherman, M., Mazzaferro, V., Bolondi, L., Craxı̀, A., Galle, P. R., Santoro, A., Beaugrand, M., Sangiovanni, A., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.014 · Cited by 822 · see citing works
Self-citationTrans-ancestry mutational landscape of hepatocellular carcinoma genomes
Totoki, Y., Tatsuno, K., Covington, K. R., Ueda, H., Creighton, C. J., Kato, M., Tsuji, S., Donehower, L. A., Slagle, B. L., Nakamura, H., et al. (2014) · Nature Genetics · doi:10.1038/ng.3126 · Cited by 781 · see citing works
Cheng, A., Kang, Y., Lin, D., Park, J., Kudo, M., Qin, S., Chung, H. C., Song, X., Xu, J., Poggi, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8372 · Cited by 777 · see citing works
Johnson, P. J., Qin, S., Park, J.-W., Poon, R. T. P., Raoul, J.-L., Philip, P. A., Hsu, C.-H., Hu, T.-H., Heo, J., Xu, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4410 · Cited by 772 · see citing works
Focal Gains of <i>VEGFA</i> and Molecular Classification of Hepatocellular Carcinoma
Chiang, D. Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., LeBlanc, A. C., Donovan, D. J., Thung, S. N., Solé, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0742 · Cited by 719 · see citing works
Self-citationLencioni, R. A., Llovet, J. M., Han, G., Tak, W. Y., Yang, J., Guglielmi, A., Paik, S. W., Reig, M., Kim, D. Y., Chau, G., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.012 · Cited by 692 · see citing works
Self-citationNault, J., Mallet, M., Pilati, C., Caldéraro, J., Bioulac‐Sage, P., Laurent, C., Laurent, A., Cherqui, D., Balabaud, C. P., & Zucman‐Rossi, J. (2013) · Nature Communications · doi:10.1038/ncomms3218 · Cited by 691 · see citing works
mRECIST for HCC: Performance and novel refinements
Llovet, J. M., & Lencioni, R. A. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.026 · Cited by 689 · see citing works
Self-citationChow, P. K. H., Gandhi, M., Tan, S. B., Khin, M. W., Khasbazar, A., Ong, J., Choo, S. P., Cheow, P. C., Chotipanich, C., Lim, K., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.0892 · Cited by 656 · see citing works
Yau, T. C. C., Park, J. W., Finn, R. S., Cheng, A., Mathurin, P., Edeline, J., Kudo, M., Han, K., Harding, J. J., Merle, P., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.029 · Cited by 647 · see citing works
Self-citationRaoul, J., Forner, A., Bolondi, L., Cheung, T. T., Kloeckner, R., & de Baère, T. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.11.002 · Cited by 643 · see citing works
The Human Cell Atlas: from vision to reality
Rozenblatt-Rosen, O., Stubbington, M. J. T., Regev, A., & Teichmann, S. A. (2017) · Nature · doi:10.1038/550451a · Cited by 638 · see citing works
Cainap, C. I., Qin, S., Huang, W., Chung, I. J., Pan, H., Cheng, Y., Kudo, M., Kang, Y., Chen, P., Toh, H.-C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3298 · Cited by 626 · see citing works
Llovet, J. M., Decaens, T., Raoul, J., Boucher, É., Kudo, M., Chang, C., Kang, Y., Assénat, E., Lim, H.-Y., Boige, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3009 · Cited by 595 · see citing works
Self-citationZhu, A. X., Rosmorduc, O., Evans, T. R. J., Ross, P. J., Santoro, A., Carrilho, F. J., Bruix, J., Qin, S., Thuluvath, P. J., Llovet, J. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.7746 · Cited by 577 · see citing works
Self-citationSystemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
Gordan, J. D., Kennedy, E. B., Abou‐Alfa, G. K., Beg, M. S., Brower, S. T., Gade, T. P. F., Goff, L. W., Gupta, S., Guy, J. E., Harris, W. P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02672 · Cited by 571 · see citing works
Self-citationLee, M. S., Ryoo, B.-Y., Hsu, C.-H., Numata, K., Stein, S., Verret, W., Hack, S. P., Spahn, J., Liu, B., Abdullah, H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30156-x · Cited by 562 · see citing works
He, M., Li, Q., Zou, R., Shen, J., Fang, W., Tan, G., Zhou, Y.-M., Wu, X., Xu, L., Wei, W., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0250 · Cited by 550 · see citing works
Implementing Genome-Driven Oncology
Hyman, D. M., Taylor, B. S., & Baselga, J. M. (2017) · Cell · doi:10.1016/j.cell.2016.12.015 · Cited by 505 · see citing works
Meyer, T., Fox, R., Ma, Y. T., Ross, P. J., James, M. W., Sturgess, R. P., Stubbs, C., Stocken, D. D., Wall, L. R., Watkinson, A. F., et al. (2017) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(17)30156-5 · Cited by 500 · see citing works
Yao, F. Y., Mehta, N. J., Flemming, J. A., Dodge, J. L., Hameed, B., Fix, O. K., Hirose, R., Fidelman, N. A., Kerlan, R. K., & Roberts, J. P. (2015) · Hepatology · doi:10.1002/hep.27752 · Cited by 485 · see citing works
The Intersection between Tumor Angiogenesis and Immune Suppression
Rahma, O. E., & Hodi, F. S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1543 · Cited by 480 · see citing works
Cancer stem cells in hepatocellular carcinoma — from origin to clinical implications
Lee, T. K., Guan, X., & Ma, S. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00508-3 · Cited by 463 · see citing works
Vogel, A., Martinelli, E., Vogel, A., Cervantes, A. M. R., Chau, I., Daniele, B., Llovet, J. M., Meyer, T., Nault, J., Neumann, U. P., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.014 · Cited by 459 · see citing works
Self-citationKelley, R. K., Sangro, B., Harris, W. P., Ikeda, M., Okusaka, T., Kang, Y., Qin, S., Tai, D. W.-M., Lim, H. Y., Yau, T. C. C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03555 · Cited by 450 · see citing works
Self-citationSawey, E. T., Chanrion, M., Cai, C., Wu, G., Zhang, J., Zender, L., Zhao, A. S., Busuttil, R. W., Yee, H. T., Stein, L. D., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.040 · Cited by 437 · see citing works
DNA methylation‐based prognosis and epidrivers in hepatocellular carcinoma
Villanueva, A., Portela, A., Sayols, S., Battiston, C., Hoshida, Y., Méndez‐González, J., Imbeaud, S., Letouzé, É., Hernández–Gea, V., Cornellà, H., et al. (2015) · Hepatology · doi:10.1002/hep.27732 · Cited by 430 · see citing works
Self-citationAhn, S., Jang, S. J., Shim, J. H., Kim, D., Hong, S., Sung, C. O., Baek, D., Haq, F., Ansari, A. A., Lee, S. Y., et al. (2014) · Hepatology · doi:10.1002/hep.27198 · Cited by 424 · see citing works
Classifying the evolutionary and ecological features of neoplasms
Maley, C. C., Aktipis, A., Graham, T. A., Sottoriva, A., Boddy, A. M., Janiszewska, M., Silva, A. S., Gerlinger, M., Yuan, Y., Pienta, K. J., et al. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.69 · Cited by 423 · see citing works
Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations
Affo, S., Nair, A., Brundu, F., Ravichandra, A., Bhattacharjee, S., Matsuda, M., Chin, L., Filliol, A., Wen, W., Song, X., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.012 · Cited by 416 · see citing works
Self-citationTrial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Llovet, J. M., Villanueva, A., Marrero, J. A., Schwartz, M., Meyer, T., Galle, P. R., Lencioni, R., Greten, T. F., Kudo, M., Mandrekar, S. J., et al. (2021) · Hepatology · doi:10.1002/hep.31327 · Cited by 413 · see citing works
Self-citationSangro, B., Melero, I., Wadhawan, S., Finn, R. S., Abou-Alfa, G. K., Cheng, A.-L., Yau, T., Furuse, J., Park, J.-W., Boyd, Z., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.026 · Cited by 407 · see citing works
Self-citationHepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
Llovet, J. M., & Hernández–Gea, V. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0547 · Cited by 397 · see citing works
Self-citationEmergence of a High-Plasticity Cell State during Lung Cancer Evolution
Marjanovic, N. D., Hofree, M., Chan, J. E., Canner, D. A., Wu, K., Trakala, M., Hartmann, G. G., Smith, O. C. G., Kim, J. Y., Evans, K. V., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.012 · Cited by 388 · see citing works
Abou-Alfa, G. K., Chan, S. L., Kudo, M., Lau, G., Kelley, R. K., Furuse, J., Sukeepaisarnjaroen, W., Kang, Y.-K., Dao, T. V., De Toni, E. N., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.4_suppl.379 · Cited by 388 · see citing works
Self-citationMarrero, J. A., Kudo, M., Venook, A. P., Ye, S.-L., Bronowicki, J., Chen, X., Dagher, L., Furuse, J., Geschwind, J.-F. H., de Guevara, L. L., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.020 · Cited by 383 · see citing works
Systemic treatment of hepatocellular carcinoma: An EASL position paper
Bruix, J., Chan, S. L., Galle, P. R., Rimassa, L., & Sangro, B. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.004 · Cited by 382 · see citing works
Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics
Nam, A. S., Chaligné, R., & Landau, D. A. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0265-5 · Cited by 381 · see citing works
Kadalayil, L., Benini, R., Pallan, L., O’Beirne, J. P., Marelli, L., Yu, D., Hackshaw, A. K., Fox, R., Johnson, P. J., Burroughs, A. K., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt247 · Cited by 370 · see citing works
Ma, L., Wang, L., Khatib, S. A., Chang, C.-W., Heinrich, S., Dominguez, D. A., Forgues, M., Candia, J., Hernandez, M. O., Kelly, M. C., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.06.028 · Cited by 370 · see citing works
Self-citationIntratumoral heterogeneity and clonal evolution in liver cancer
Losic, B., Craig, A. J., Villacorta-Martín, C., Martins-Filho, S. N., Akers, N. K., Chen, X., Ahsen, M. E., von Felden, J., Labgaa, I., D’Avola, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14050-z · Cited by 364 · see citing works
Self-citationKudo, M., Han, G., Finn, R. S., Poon, R. T. P., Blanc, J., Yan, L., Yang, J., Lu, L., Tak, W. Y., Yu, X., et al. (2014) · Hepatology · doi:10.1002/hep.27290 · Cited by 352 · see citing works
Single‐cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma
Zheng, H., Pomyen, Y., Hernandez, M. O., Li, C., Livák, F., Tang, W., Dang, H. T., Greten, T. F., Davis, J. L., Zhao, Y., et al. (2018) · Hepatology · doi:10.1002/hep.29778 · Cited by 350 · see citing works
Self-citationRimassa, L., Assénat, E., Peck‐Radosavljevic, M., Pracht, M., Zagonel, V., Mathurin, P., Caremoli, E. R., Porta, C., Daniele, B., Bolondi, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30146-3 · Cited by 350 · see citing works
Finn, R. S., Merle, P., Granito, A., Huang, Y., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Gerolami, R., Caparello, C., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.04.010 · Cited by 347 · see citing works
Lachenmayer, A., Alsinet, C., Savic, R., Cabellos, L., Toffanin, S., Hoshida, Y., Villanueva, A., Minguez, B., Newell, P., Tsai, H.-W., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2322 · Cited by 306 · see citing works
Self-citationGenetic and non-genetic clonal diversity in cancer evolution
Black, J. R., & McGranahan, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00336-2 · Cited by 287 · see citing works
Kim, R. D., Sarker, D., Meyer, T., Yau, T. C. C., Macarulla, T. M., Park, J., Choo, S. P., Hollebecque, A., Sung, M. W., Lim, H.-Y., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0555 · Cited by 276 · see citing works
Self-citationPinyol, R., Torrecilla, S., Wang, H., Montironi, C., Piqué‐Gili, M., Torres‐Martín, M., Leow, W. Q., Willoughby, C. E., Ramadori, P., Andreu-Oller, C., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.04.049 · Cited by 257 · see citing works
Self-citationGellert‐Kristensen, H., Richardson, T. G., Smith, G. D., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Stender, S. (2020) · Hepatology · doi:10.1002/hep.31238 · Cited by 255 · see citing works
Single-cell technologies in hepatology: new insights into liver biology and disease pathogenesis
Ramachandran, P., Matchett, K. P., Dobie, R., Wilson-Kanamori, J. R., & Henderson, N. C. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0304-x · Cited by 253 · see citing works
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification
Montironi, C., Castet, F., Haber, P. K., Pinyol, R., Torres-Martin, M., Torrens, L., Mesropian, A., Wang, H., Puigvehi, M., Maeda, M., et al. (2023) · Gut · doi:10.1136/gutjnl-2021-325918 · Cited by 253 · see citing works
Self-citationRizvi, A. H., Camara, P. G., Kandror, E. K., Roberts, T. J., Schieren, I., Maniatis, T., & Rabadan, R. (2017) · Nature Biotechnology · doi:10.1038/nbt.3854 · Cited by 248 · see citing works
Haber, P. K., Puigvehí, M., Castet, F., Lourdusamy, V., Montal, R., Tabrizian, P., Buckstein, M., Kim, E., Villanueva, A., Schwartz, M., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.06.008 · Cited by 248 · see citing works
Self-citationDistributed hepatocytes expressing telomerase repopulate the liver in homeostasis and injury
Lin, S., Nascimento, E. M., Gajera, C. R., Chen, L., Neuhöfer, P., Garbuzov, A., Wang, S., & Artandi, S. E. (2018) · Nature · doi:10.1038/s41586-018-0004-7 · Cited by 241 · see citing works
Chen, L.-T., Martinelli, E., Cheng, A., Pentheroudakis, G. E., Qin, S., Bhattacharyya, G. S., Ikeda, M., Lim, H. Y., Ho, G. F., Choo, S. P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.12.001 · Cited by 238 · see citing works
Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
Llovet, J. M., Montal, R., & Villanueva, A. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.01.028 · Cited by 233 · see citing works
Self-citationMicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a
Toffanin, S., Hoshida, Y., Lachenmayer, A., Villanueva, A., Cabellos, L., Minguez, B., Savic, R., Ward, S. C., Thung, S., Chiang, D. Y., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.009 · Cited by 232 · see citing works
Self-citationEarly dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
Reig, M., Torres, F., de Lope, C. R., Forner, A., Llarch, N., Rimola, J., Darnell, A., Ríos, J., Ayuso, C., & Bruix, J. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.03.030 · Cited by 228 · see citing works
Xue, R., Li, R., Guo, H., Guo, L., Su, Z., Ni, X., Qi, L., Zhang, T., Li, Q., Zhang, Z., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.033 · Cited by 214 · see citing works
Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas
Ding, X., He, M., Chan, A. W. H., Song, Q. X., Sze, S. C., Chen, H., Man, K., Man, K., Chan, S. L., Lai, P. B. S., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.09.005 · Cited by 208 · see citing works
Self-citationWang, K., Lim, H. Y., Shi, S. T., Lee, J., Deng, S., Xie, T., Zhu, Z., Wang, Y., Pocalyko, D. J., Yang, W. J., et al. (2013) · Hepatology · doi:10.1002/hep.26402 · Cited by 206 · see citing works
Luo, X., Wu, K., & He, X. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01968-w · Cited by 203 · see citing works
Park, J., Kim, Y. J., Kim, D. Y., Bae, S. H., Paik, S. W., Lee, Y. J., Kim, H. Y., Lee, H. C., Han, S. Y., Cheong, J. Y., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.11.029 · Cited by 198 · see citing works
Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma
Guo, M., Zhang, H., Zheng, J., & Liu, Y. (2020) · Journal of Cancer · doi:10.7150/jca.39972 · Cited by 185 · see citing works
Pragmatic issues in biomarker evaluation for targeted therapies in cancer
Gramont, A. D. E., Watson, S., Ellis, L. M., Rodon, J. A., Tabernero, J. M., de Gramont, A., & Hamilton, S. R. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.202 · Cited by 174 · see citing works
Cell Plasticity in Liver Regeneration
Li, W., Li, L., & Hui, L. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.01.007 · Cited by 167 · see citing works
Singal, A. G., Hoshida, Y., Pinato, D. J., Marrero, J. A., Nault, J., Paradis, V., Tayob, N., Sherman, M., Lim, Y., Feng, Z., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.01.233 · Cited by 164 · see citing works
Self-citationUm, T.-H., Kim, H., Oh, B.-K., Kim, M. S., Kim, K. S., Jung, G., & Park, Y. N. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.021 · Cited by 159 · see citing works
Bayard, Q., Meunier, L., Péneau, C., Renault, V., Shinde, J., Nault, J., Mami, I., Couchy, G., Amaddeo, G., Tubacher, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07552-9 · Cited by 156 · see citing works
Torrecilla, S., Sia, D., Harrington, A. N., Zhang, Z., Cabellos, L., Cornellà, H., Moeini, A., Campreciós, G., Leow, W., Fiel, M., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.08.013 · Cited by 152 · see citing works
Self-citationVincenzi, B., Maïo, M. D., Silletta, M., D’Onofrio, L., Spoto, C., Piccirillo, M. C., Daniele, G., Comito, F., Maci, E., Bronte, G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133488 · Cited by 150 · see citing works
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma
Haber, P. K., Castet, F., Torres-Martin, M., Andreu-Oller, C., Puigvehí, M., Miho, M., Radu, P., Dufour, J.-F., Verslype, C., Zimpel, C., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2022.09.005 · Cited by 145 · see citing works
Self-citationLiquid biopsy in the clinical management of hepatocellular carcinoma
von Felden, J., Garcia-Lezana, T., Schulze, K., Losic, B., & Villanueva, A. (2020) · Gut · doi:10.1136/gutjnl-2019-320282 · Cited by 141 · see citing works
Self-citationMartinez-Quetglas, I., Pinyol, R., Dauch, D., Torrecilla, S., Tovar, V., Moeini, A., Alsinet, C., Portela, A., Rodríguez‐Carunchio, L., Solé, M., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.09.001 · Cited by 130 · see citing works
Self-citationTao, Y., Ruan, J., Yeh, S., Lu, X., Wang, Y., Zhai, W., Cai, J., Ling, S., Gong, Q., Chong, Z., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108715108 · Cited by 129 · see citing works
Labgaa, I., Villacorta-Martín, C., D’Avola, D., Craig, A. J., von Felden, J., Martins-Filho, S. N., Sia, D., Stueck, A., Ward, S. C., Fiel, M. I., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0206-3 · Cited by 115 · see citing works
Self-citationAbou‐Alfa, G. K., Shi, Q., Knox, J. J., Kaubisch, A., Niedzwiecki, D., Posey, J. A., Tan, B. R., Kavan, P., Goel, R., Lammers, P. E., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2792 · Cited by 115 · see citing works
Self-citationAcquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma
Hatlen, M. A., Schmidt‐Kittler, O., Sherwin, C. A., Rozsahegyi, E., Rubin, N. T., Sheets, M. P., Kim, J. L., Miduturu, C. V., Bifulco, N., Brooijmans, N., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0367 · Cited by 115 · see citing works
DNA Methylation Profiling of Human Hepatocarcinogenesis
Hernandez‐Meza, G., von Felden, J., Gonzalez‐Kozlova, E., García‐Lezana, T., Peix, J., Portela, A., Craig, A. J., Sayols, S., Schwartz, M., Losic, B., et al. (2020) · Hepatology · doi:10.1002/hep.31659 · Cited by 114 · see citing works
Self-citationNingarhari, M., Caruso, S., Hirsch, T. Z., Bayard, Q., Franconi, A., Védié, A., Noblet, B., Blanc, J., Amaddeo, G., Ganne‐Carrié, N., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.052 · Cited by 113 · see citing works
Heinrich, S., Craig, A. J., Ma, L., Heinrich, B., Greten, T. F., & Wang, X. W. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.036 · Cited by 104 · see citing works
Self-citationLlovet, J. M., Decaens, T., Raoul, J., et al. (2012) · Journal of Hepatology · doi:10.1016/s0168-8278(12)61409-3 · Cited by 100 · see citing works
Self-citationJouve, J., Lecomte, T., Bouché, O., Barbier, E., Akouz, F. K., Riachi, G., Khac, É. N., Ollivier-Hourmand, I., Debette-Gratien, M., Faroux, R., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.021 · Cited by 99 · see citing works
Huang, A., Zhao, X., Yang, X.-R., Li, F.-Q., Zhou, X., Wu, K., Zhang, X., Sun, Q.-M., Cao, Y., Zhu, H., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.005 · Cited by 97 · see citing works
Self-citationRole of locoregional therapies in the wake of systemic therapy
Palmer, D. H., Malagari, K. S., & Kulik, L. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.023 · Cited by 94 · see citing works
ZNRF3 and RNF43 cooperate to safeguard metabolic liver zonation and hepatocyte proliferation
Sun, T., Annunziato, S., Bergling, S., Sheng, C., Orsini, V., Forcella, P., Pikiolek, M., Kancherla, V., Holwerda, S., Imanci, D., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.05.013 · Cited by 84 · see citing works
Lim, H. Y., Merle, P., Weiss, K. H., Yau, T. C. C., Ross, P. J., Mazzaferro, V., Blanc, J., Ma, Y. T., Yen, C. J., Kocsis, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3588 · Cited by 83 · see citing works
Self-citationMolecular profiling of hepatocellular carcinoma using circulating cell-free DNA
Kaseb, A., Sanchez, N. S., Sen, S., Kelley, R., Tan, B., Bocobo, A., Lim, K., Abdel-Wahab, R., Uemura, M., Pestana, R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3341 · Cited by 66 · see citing works
Self-citationRebouissou, S., Bella, T. L., Rekik, S., Imbeaud, S., Calatayud, A.-L., Rohr‐Udilova, N., Martin, Y., Couchy, G., Bioulac‐Sage, P., Grasl‐Kraupp, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3118 · Cited by 64 · see citing works
Rochigneux, P., Chanez, B., de Rauglaudre, B., Mitry, E., Chabannon, C., & Gilabert, M. (2021) · Cancers · doi:10.3390/cancers13020271 · Cited by 64 · see citing works
Understanding the Cause and Consequence of Tumor Heterogeneity
Khatib, S. A., Pomyen, Y., Dang, H. T., & Wang, X. W. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.01.010 · Cited by 62 · see citing works
Self-citationKelley, R. K., Oliver, J. W., Hazra, S., Benzaghou, F., Yau, T. C. C., Cheng, A., & Rimassa, L. (2020) · Future Oncology · doi:10.2217/fon-2020-0283 · Cited by 62 · see citing works
Self-citationShen, Y., Hsu, C., Jeng, Y., Ho, M., Ho, C., Yeh, C.-P., Yeh, C.-Y., Hsu, M.-C., Hu, R., & Cheng, A. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.032 · Cited by 61 · see citing works
Bassaganyas, L., Pinyol, R., Esteban-Fabró, R., Torrens, L., Torrecilla, S., Willoughby, C. E., Franch-Expósito, S., Vila-Casadesús, M., Salaverria, I., Montal, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1497 · Cited by 58 · see citing works
Self-citationGlypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma
Shih, T., Wang, L., Wang, H., et al. (2020) · Liver Research · doi:10.1016/j.livres.2020.11.003 · Cited by 54 · see citing works
Docta, R. Y., Ferronha, T., Sanderson, J. P., et al. (2018) · Hepatology · doi:10.1002/hep.30477 · Cited by 53 · see citing works
Kim, H., Bang, Y. H., Lee, M. A., et al. (2020) · Liver International · doi:10.1111/liv.14573 · Cited by 46 · see citing works
Meunier, L., Hirsch, T. Z., Caruso, S., Imbeaud, S., Bayard, Q., Roehrig, A., Couchy, G., Nault, J., Llovet, J. M., Blanc, J., et al. (2021) · Hepatology · doi:10.1002/hep.31796 · Cited by 45 · see citing works
Self-citationDíaz‐González, Á., Sanduzzi‐Zamparelli, M., Sapena, V., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15088 · Cited by 44 · see citing works
Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.
Haber, P. K., Torres‐Martín, M., Dufour, J., Verslype, C., Marquardt, J. U., Galle, P. R., Vogel, A., Meyer, T., Labgaa, I., Roberts, L. R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.4100 · Cited by 37 · see citing works
Self-citationAttallah, A. M., Omran, M. M., Attallah, A. A., ABDALLAH, S. O., Farid, K., Darwish, H., El‐Dosoky, I., & Shaker, Y. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.481 · Cited by 36 · see citing works
Hlady, R. A., Zhao, X., Khoury, L. Y. E., et al. (2021) · Hepatology · doi:10.1002/hep.32111 · Cited by 36 · see citing works
Sung, M. W., Finn, R. S., Qin, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.4_suppl.317 · Cited by 32 · see citing works
Bruno, S., Sanchez, M. B. H., Chiabotto, G., Fonsato, V., Navarro‐Tableros, V., Pasquino, C., Tapparo, M., & Camussi, G. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.644088 · Cited by 32 · see citing works
Mutational Processes in Hepatocellular Carcinoma: The Story of Aristolochic Acid
Nault, J., & Letouzé, E. (2019) · Seminars in liver disease (Print) · doi:10.1055/s-0039-1685516 · Cited by 27 · see citing works
Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials
Noonan, A. M., & Pawlik, T. M. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1677606 · Cited by 27 · see citing works
Hepatocyte apoptosis is tumor promoting in murine nonalcoholic steatohepatitis
Hirsova, P., Böhm, F., Dohnalkova, E., Nožičková, B., Heikenwalder, M., Gores, G., & Weber, A. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2283-9 · Cited by 27 · see citing works
Self-citationIkeda, M., Okusaka, T., Ohno, I., et al. (2021) · Immunotherapy · doi:10.2217/imt-2020-0278 · Cited by 25 · see citing works
Llovet, J. M., Singal, A. G., Villanueva, A., Finn, R. S., Kudo, M., Galle, P. R., Ikeda, M., Callies, S., McGrath, L. M., Wang, C., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4000 · Cited by 19 · see citing works
Self-citationYau, T. C. C., Lee, J. J. X., Wong, J. S. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.e16181 · Cited by 4 · see citing works
Flagged first, then by citations
Research works printed but not linked: 3
- [20][Press Release] FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma (2020).
- [94][Press Release-28/06/2021] Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Live
- [137][Press Release] Merck Announces KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Overall Survival (OS) in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib - Merck.com.
Cited by
Sorted by citations
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052 · see citing works
“[331] Noninvasive criteria for the presence of varices (e.g., Baveno VI criteria) have not been validated in patients with HCC.”
Self-citationAdjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391 · see citing works
Self-citationNonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Llovet, J. M., Willoughby, C. E., Singal, A. G., Greten, T. F., Heikenwälder, M., El-Serag, H. B., Finn, R. S., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00754-7 · Cited by 354 · see citing works
Self-citationCappuyns, S., Corbett, V., Yarchoan, M., Finn, R. S., & Llovet, J. M. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2023.2677 · Cited by 167 · see citing works
Self-citationGajos-Michniewicz, A., & Czyz, M. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.050 · Cited by 89 · see citing works
Exploring a new pathway for biomarker-based approval of immunotherapies
Llovet, J. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00731-8 · Cited by 16 · see citing works
Self-citation
- Authors
- Llovet, J. M., Pinyol, R., Kelley, R. K., El-Khoueiry, A., Reeves, H. L., Wang, X. W., Gores, G. J., & Villanueva, A.
- Affiliations
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Hospital Clínic de Barcelona (ES)
- University of California, San Francisco (US)
- University of Southern California (US)
- Freeman Hospital (GB)
- National Cancer Institute (US)
- Mayo Clinic (US)
- Tisch Cancer Institute (US)
- Corresponding author
- Llovet, Josep M.
- ORCID
- Venue
- Nature Cancer
- Published
- 2022-04-28
- Volume
- 3
- Issue
- 4
- Pages
- 386-401
- ISSN
- 2662-1347 (ISSN-L)
- PMC
- PMC9060366
- OpenAlex
- W4225146220
- Cited by
- 498
- References
- 174
- Citations by year
- 2026: 90 · 2025: 145 · 2024: 157 · 2023: 92 · 2022: 14
- FWCI
- 17.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Cancer Research UK (26813)
- National Institutes of Health
- National Cancer Institute (Z01BC010313, Z01BC010876, Z01BC010877, ZIABC011870)
- National Institute of Diabetes and Digestive and Kidney Diseases (R56DK056621, R01DK056621, R01DK128289)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- hepatocellular carcinoma, molecular pathogenesis, tumor heterogeneity, systemic therapy, immunotherapy, combination therapy, treatment resistance, predictive biomarkers, sequential therapy, patient selection, patient monitoring
- MeSH terms
- Combined Modality Therapy, Carcinoma, Hepatocellular, Humans, Immunotherapy, Liver Neoplasms, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
